3,7-diazabicyclo-[3.3.0]oct-1(5)-ene | 770695-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: 3,7-diazabicyclo-[3.3.0]oct-1(5)-ene
• 英文别名: Hexahydropyrrolo[3,4-c]pyrrole；1,2,3,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole
• CAS: 770695-31-3
• 化学式: C₆H₁₀N₂
• 分子量: 110.159
• InChiKey: HWUGBMMPIAIJJC-UHFFFAOYSA-N

物化性质

• 沸点：
  257.9±29.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,7-diazabicyclo-[3.3.0]oct-1(5)-ene 、 1-环丙基-6,7,8-三氟-4-氧代-1,4-二氢喹啉-3-羧酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 以 乙腈 为溶剂， 以80%的产率得到1-cyclopropyl-6,8-difluoro-7-<3,7-diazabicyclo<3.3.0>oct-1(5)-en-3-yl>-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Quinolone compounds and a process for their preparation

  摘要：

  通式喹诺酮化合物的药物组合物对抗细菌感染具有活性，包含这种化合物，制造喹诺酮化合物和组合物的过程以及利用喹诺酮化合物制造用于治疗细菌感染的药物组合物。

  公开号：

  EP0424850A1

文献信息

• 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Babin Didier

  公开号：US20120208809A1

  公开（公告）日：2012-08-16

  The invention relates to novel 9H-pyrrolo[2,3-b:5,4-c′]dipyridine azacarbolines of formula (I), where: Z2, Z3, and Z4 are CH, CRa, CRs, or N; R3 is H, Hal; CF3, CHF2; OH, alkoxy; NH2, NH (alkyl), N(alkyl)2; C(O)O alkyl; CONH(alkyl), CON(alkyl)2; C1-C10 alkyl; aryl; heteroaryl; R6 is heteroaryl; Ra is CONH2, CONH alkyl, CONH cycloalkyl; CONH heterocycloalkyl; CON(alkyl)2; CON(alkyl)(heterocycloalkyl); CONHN(alkyl)2; C(O)heterocycloalkyl; Rs is H; Hal, OH; O-alkyl(C1-C10); NH2; N(alkyl(C1-C10) or cycloalkyl(C3-C7))2; NHC(O)R3a; N(alkyl(C1-C10)C(O)R3a; NHS(O2)R3a; N(alkyl)(C1-C10)S(O2)R3a; CO2R3a; SR3a; S(O)R3a; S(O2)R3a; Ra and Rs optionally form a cycle; R3a is selected from among Hal, CF3, C1-C10 alkyl; C3-C7 cycloalkyl; C2-C6 alkenyl; C2-C6 alkynyl; OH; O-alkyl(C1-C10); (C3-C7); heterocycloalkyl (C3-C7); NH2; NH-(alkyl(C1-C10) or cycloalkyl(C3-C7)); N(alkyl(C1-C10) or cycloalkyl(C3-C7))2; NH-(alkyl(C1-C10) or heterocycloalkyl(C3-C7)); N(alkyl(C1-C10) or heterocycloalkyl(C3-C7))2, as well as to the isomers and salts of said substances of formula (I) and to the therapeutic use thereof for treating cancer.

  该发明涉及公式（I）的新型9H-吡咯[2,3-b:5,4-c′]二吡啶氮杂碳醇，其中：Z2、Z3和Z4为CH、CRa、CRs或N；R3为H、Hal、CF3、CHF2、OH、烷氧基、NH2、NH（烷基）、N（烷基）2、C（O）O烷基、CONH（烷基）、CON（烷基）2、C1-C10烷基、芳基、杂环芳基；R6为杂环芳基；Ra为CONH2、CONH烷基、CONH环烷基、CONH杂环烷基、CON（烷基）2、CON（烷基）（杂环烷基）、CONHN（烷基）2、C（O）杂环烷基；Rs为H、Hal、OH、O-烷基（C1-C10）、NH2、N（烷基（C1-C10）或环烷基（C3-C7））2、NHC（O）R3a、N（烷基（C1-C10）C（O）R3a、NHS（O2）R3a、N（烷基）（C1-C10）S（O2）R3a、CO2R3a、SR3a、S（O）R3a、S（O2）R3a；Ra和Rs可选择形成环；R3a从Hal、CF3、C1-C10烷基、C3-C7环烷基、C2-C6烯基、C2-C6炔基、OH、O-烷基（C1-C10）、（C3-C7）、杂环烷基（C3-C7）、NH2、NH-（烷基（C1-C10）或环烷基（C3-C7））、N（烷基（C1-C10）或环烷基（C3-C7））2、NH-（烷基（C1-C10）或杂环烷基（C3-C7））、N（烷基（C1-C10）或杂环烷基（C3-C7））2中选择，以及所述公式（I）的异构体和盐，以及其治疗用途，用于治疗癌症。
• [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases
  申请人：Dahnke Karl Robert

  公开号：US20080306082A1

  公开（公告）日：2008-12-11

  The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.

  本发明提供了一种公式I的化合物：用于治疗癌症和炎症性疾病。
• [EN] NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA<br/>[FR] NOUVEAUX COMPOSÉS APPROPRIÉS POUR LE TRAITEMENT DE LA DYSLIPIDÉMIE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2021130723A1

  公开（公告）日：2021-07-01

  The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation The present invention is directed towards compounds which can be useful in treating diseases such as Hyperlipidemia and also have a beneficial effect on lowering cholesterol.

  本发明涉及一般式（I）的化合物，它们的互变异构体，立体异构体，药学上可接受的盐，含有它们的药物组合物，它们的制备方法，这些化合物在医学上的应用以及其制备中涉及的中间体。本发明针对的是可以用于治疗高脂血症等疾病并且对降低胆固醇有益的化合物。
• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• Benzimidazole compounds as ORL1-receptor agonists
  申请人：——

  公开号：US20020049212A1

  公开（公告）日：2002-04-25

  A compound of the formula: 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted, mono-, di- or tri-substituted (C 3 -C 11 )cycloalkyl or (C 3 -C 11 )cycloalkenyl or the like, A is unsubstituted (C 1 -C 7 )alkyl or (C 2 -C 5 )alkenyl, hydroxy-(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy-(C═O), or unsubstituted, mono-, di- or tri- substituted aryl, or aromatic-heterocyclic or the like, M is a covalent bond O, S, NH or the like, Y is 4- to 12-membered bicyclic-carbocyclic rings or 4- to 12-membered bicyclic-heterocyclic rings, or 5- to 17 membered spirocarbocyclic rings or 5- to 17-membered spiroheterocyclic rings or the like, Z 1 , Z 2 , Z 3 and Z 4 are hydrogen or the like, is disclosed. These compounds have ORL 1 -receptor agonist activity, and are thus useful as analgesics or the like in mammalian subjects.

  一种化合物的公式：1或其药学上可接受的盐，其中R1为未取代、单取代、双取代或三取代的（C3-C11）环烷基或（C3-C11）环烯基等，A为未取代的（C1-C7）烷基或（C2-C5）烯基、羟基-(C1-C4)烷基、（C1-C4）氧基-(C═O)，或未取代、单取代、双取代或三取代芳基、芳香杂环或类似物，M为共价键O、S、NH或类似物，Y为4-至12-成员双环碳环或4-至12-成员双环杂环，或5-至17-成员螺环碳环或5-至17-成员螺环杂环或类似物，Z1、Z2、Z3和Z4为氢或类似物。这些化合物具有ORL1受体激动剂活性，因此在哺乳动物主体中可用作镇痛剂或类似物。